Skip Navigation


Epidemiologic Reviews Advance Access originally published online on June 5, 2006
Epidemiologic Reviews 2006 28(1):112-125; doi:10.1093/epirev/mxj009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/1/112    most recent
mxj009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shepard, C. W.
Right arrow Articles by Bell, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shepard, C. W.
Right arrow Articles by Bell, B. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Epidemiologic Reviews Copyright © 2006 by the Johns Hopkins Bloomberg School of Public Health All rights reserved; printed in U.S.A.

ARTICLES

Hepatitis B Virus Infection: Epidemiology and Vaccination

Colin W. Shepard, Edgar P. Simard, Lyn Finelli, Anthony E. Fiore and Beth P. Bell

From the Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Correspondence to Dr. Anthony E. Fiore, Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS G37, Atlanta, GA 30333 (e-mail: abf4{at}cdc.gov).

accepted for publication March 28, 2006.

Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma. This comprehensive review of hepatitis B epidemiology and vaccines focuses on definitive and influential studies and highlights current trends, policies, and directions. HBV can be transmitted vertically, through sexual or household contact, or by unsafe injections, but chronic infections acquired during infancy or childhood account for a disproportionately large share of worldwide morbidity and mortality. Vaccination against HBV infection can be started at birth and provides long-term protection against infection in more than 90% of healthy people. In the 1990s, many industrialized countries and a few less-developed countries implemented universal hepatitis B immunization and experienced measurable reductions in HBV-related disease. For example, in Taiwan, the prevalence of chronic infection in children declined by more than 90%. Many resource-poor nations have recently initiated universal hepatitis B immunization programs with assistance from the Global Alliance for Vaccines and Immunization. Further progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.

hepatitis B • hepatitis B vaccines • hepatitis B virus • immunization programs

anti-HBs, antibody to hepatitis B surface antigenHBeAg, hepatitis B e antigenHBsAg, hepatitis B surface antigenHBV, hepatitis B virusMSM, men who have sex with men


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Pediatr. Rev.Home page
A. R. Davis and P. Rosenthal
Hepatitis B in Children
Pediatr. Rev., April 1, 2008; 29(4): 111 - 120.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. L. Sedjo, T. Byers, E. Barrera Jr., C. Cohen, E. T. H. Fontham, L. A. Newman, C. D. Runowicz, A. G. Thorson, M. J. Thun, E. Ward, et al.
A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
CA Cancer J Clin, November 1, 2007; 57(6): 326 - 340.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
D. Candotti, K. Danso, and J.-P. Allain
Maternofetal transmission of hepatitis B virus genotype E in Ghana, west Africa
J. Gen. Virol., October 1, 2007; 88(10): 2686 - 2695.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Valsamakis
Molecular Testing in the Diagnosis and Management of Chronic Hepatitis B
Clin. Microbiol. Rev., July 1, 2007; 20(3): 426 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. R. Langley, A. W. Walsh, C. J. Baldick, B. J. Eggers, R. E. Rose, S. M. Levine, A. J. Kapur, R. J. Colonno, and D. J. Tenney
Inhibition of Hepatitis B Virus Polymerase by Entecavir
J. Virol., April 15, 2007; 81(8): 3992 - 4001.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. J. Tenney, R. E. Rose, C. J. Baldick, S. M. Levine, K. A. Pokornowski, A. W. Walsh, J. Fang, C.-F. Yu, S. Zhang, C. E. Mazzucco, et al.
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
Antimicrob. Agents Chemother., March 1, 2007; 51(3): 902 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Epidemiol RevHome page
M. A. Ibrahim
Editorial: Vaccines and Public Health
Epidemiol. Rev., August 1, 2006; 28(1): 1 - 2.
[Full Text] [PDF]

Home page
 Am J EpidemiolHome page
A. R. Hinman, W. A. Orenstein, and L. E. Rodewald
Vaccines--Victories and Challenges
Am. J. Epidemiol., August 1, 2006; 164(3): 197 - 199.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.